Bugat R - Search Results

1

Gastric mucosal lesions produced by intravenous infusion of aspirin in cats.

Bugat R, Thompson MR, Aures D, Grossman MI. Bugat R, et al. Gastroenterology. 1976 Nov;71(5):754-9. Gastroenterology. 1976. PMID: 9330

2

Detection of a circulating gastric secretagogue in plasma extracts from normogastrinemic patients with acid hypersecretion.

Bugat R, Walsh JH, Ippoliti A, Elashoff J, Grossman MI. Bugat R, et al. Gastroenterology. 1976 Dec;71(6):1114-6. Gastroenterology. 1976. PMID: 992275

3

[Cardiotoxicity of continuous intravenous infusion of 5-fluorouracil: clinical study, prevention and physiopathology. Apropos of 13 cases].

de Forni M, Bugat R, Sorbette F, Delay M, Bachaud JM, Chevreau C. de Forni M, et al. Among authors: bugat r. Bull Cancer. 1990;77(5):429-38. Bull Cancer. 1990. PMID: 2205312 Review. French.

4

Mechanism-based models for topotecan-induced neutropenia.

Léger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E. Léger F, et al. Among authors: bugat r. Clin Pharmacol Ther. 2004 Dec;76(6):567-78. doi: 10.1016/j.clpt.2004.08.008. Clin Pharmacol Ther. 2004. PMID: 15592328

5

Combination chemotherapy of vinorelbine and cisplatin: a phase I pharmacokinetic study in patients with metastatic solid tumors.

Delord JP, Puozzo C, Lefresne F, Bugat R. Delord JP, et al. Among authors: bugat r. Anticancer Res. 2009 Feb;29(2):553-60. Anticancer Res. 2009. PMID: 19331202 Free article. Clinical Trial.

6

Population pharmacokinetics of oxaliplatin.

Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E. Delord JP, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. doi: 10.1007/s00280-002-0550-3. Epub 2002 Dec 4. Cancer Chemother Pharmacol. 2003. PMID: 12647013

7

The effects of food on the pharmacokinetic profile of oral vinorelbine.

Bugat R, Variol P, Roché H, Fumoleau P, Robinet G, Senac I. Bugat R, et al. Cancer Chemother Pharmacol. 2002 Oct;50(4):285-90. doi: 10.1007/s00280-002-0475-x. Epub 2002 Aug 15. Cancer Chemother Pharmacol. 2002. PMID: 12357302 Clinical Trial.

8

Individual adaptive dosing of topotecan in ovarian cancer.

Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: bugat r. Clin Cancer Res. 2002 Feb;8(2):394-9. Clin Cancer Res. 2002. PMID: 11839654 Clinical Trial.

9

Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.

Delord JP, Léger F, Canal P, Poublanc M, Bugat R, Chatelut E. Delord JP, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2006 Aug;58(2):189-94. doi: 10.1007/s00280-005-0142-0. Epub 2005 Nov 22. Cancer Chemother Pharmacol. 2006. PMID: 16328415 Clinical Trial.

10

Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.

Léger F, Loos WJ, Fourcade J, Bugat R, Goffinet M, Mathijssen RH, Verweij J, Sparreboom A, Chatelut E. Léger F, et al. Among authors: bugat r. Br J Cancer. 2004 Jan 26;90(2):343-7. doi: 10.1038/sj.bjc.6601469. Br J Cancer. 2004. PMID: 14735174 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results